» Articles » PMID: 32671331

Where Does TIPS Fit in the Management of Patients with Cirrhosis?

Overview
Journal JHEP Rep
Specialty Gastroenterology
Date 2020 Jul 17
PMID 32671331
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

In this review, we summarise the current knowledge on the indications and contraindications of transjugular intrahepatic portosystemic shunt (TIPS) placement for the treatment of the complications of portal hypertension in cirrhosis, specifically variceal haemorrhage and ascites. Moreover, we discuss the role of TIPS for the treatment of portal vein thrombosis (PVT) and the prevention of complications after extrahepatic surgery ('preoperative TIPS') in patients with cirrhosis. The position of TIPS in the treatment hierarchy depends on the clinical setting and on patient characteristics. In acute variceal haemorrhage, preemptive TIPS is indicated in patients at a high risk of failing standard therapy, that is those with a Child-Pugh score of 10-13 points or Child-Pugh B with active bleeding at endoscopy, although the survival benefit in the latter group still remains to be established. Non-preemptive TIPS is a second-line therapy for the prevention of recurrent variceal haemorrhage and for the treatment of ascites. Of note, TIPS may also improve sarcopenia. Contraindications to TIPS placement, independent of clinical setting, include very advanced disease (Child-Pugh >13 points), episodes of recurrent overt hepatic encephalopathy without an identifiable precipitating factor, heart failure, and pulmonary hypertension. In patients with PVT, TIPS placement not only controls complications of portal hypertension, but also promotes portal vein recanalisation. Although the severity of portal hypertension correlates with poor outcomes after extrahepatic surgery, there is no evidence to recommend preoperative TIPS placement.

Citing Articles

Comparison of clinical outcomes of transjugular intrahepatic portosystemic shunt for refractory ascites and recurrent nonrefractory ascites.

Luo S, Zhang H, Liu W, Chu J, Chen J World J Hepatol. 2025; 17(2):100451.

PMID: 40027559 PMC: 11866158. DOI: 10.4254/wjh.v17.i2.100451.


Predictive value of neutrophil-to-lymphocyte ratio for long-term adverse outcomes in cirrhosis patients post-transjugular intrahepatic portosystemic shunt.

Zhang Q, Xu Z, Long L, Luo X, Wang R, Zhu K Sci Rep. 2025; 15(1):797.

PMID: 39755906 PMC: 11700169. DOI: 10.1038/s41598-024-84630-7.


Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide.

Protopapas A, Tsankof A, Papagiouvanni I, Kaiafa G, Skoura L, Savopoulos C World J Hepatol. 2025; 16(12):1377-1394.

PMID: 39744202 PMC: 11686542. DOI: 10.4254/wjh.v16.i12.1377.


Value of systemic inflammation markers for the detection of minimal and prediction of overt hepatic encephalopathy after TIPS insertion.

Tiede A, Stockhoff L, Ehrenbauer A, Rieland H, Cornberg M, Meyer B Metab Brain Dis. 2024; 40(1):58.

PMID: 39656322 PMC: 11632008. DOI: 10.1007/s11011-024-01436-2.


Portocaval shunts' role in gut microbiota and hepatic encephalopathy: The gut-to-brain pathway.

Yakut A World J Gastroenterol. 2024; 30(43):4672-4676.

PMID: 39575404 PMC: 11572643. DOI: 10.3748/wjg.v30.i43.4672.


References
1.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A . Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2016; 152(1):157-163. DOI: 10.1053/j.gastro.2016.09.016. View

2.
Angeli P, Garcia-Tsao G, Nadim M, Parikh C . News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019; 71(4):811-822. DOI: 10.1016/j.jhep.2019.07.002. View

3.
Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H . Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2010; 46(1):78-85. DOI: 10.1007/s00535-010-0282-9. View

4.
Vidal V, Joly L, Perreault P, Bouchard L, Lafortune M, Pomier-Layrargues G . Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients. Cardiovasc Intervent Radiol. 2005; 29(2):216-9. DOI: 10.1007/s00270-004-0346-4. View

5.
Escorsell A, Banares R, Garcia-Pagan J, Gilabert R, Moitinho E, Piqueras B . TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology. 2002; 35(2):385-92. DOI: 10.1053/jhep.2002.30418. View